Effects of glucagon-like peptide-1 receptor agonists on managing high blood pressure

Clinical trials show modest yet statistically significant reductions in systolic blood pressure with glucagon-like peptide-1 receptor agonists.

• GLP-1 receptor agonists may influence blood pressure through mechanisms such as nervous system modulation, widening of blood vessels, and increased urine production.
• The effects on systolic blood pressure are more consistent compared to those on diastolic blood pressure.
• Emerging dual receptor agonists combining GLP-1 and GIP could enhance hypertension management strategies.
• GLP-1 receptor agonists may serve as additional treatments for hypertension in patients also treated for other cardiometabolic conditions.
• The blood pressure-lowering effects of GLP-1 receptor agonists appear to be independent of weight loss or blood sugar control.

Simplified